UPDATE: Oppenheimer Downgraded Zalicus
November 11, 2013 at 15:48 PM EST
In a report published Monday, Oppenheimer analyst Boris Peaker downgraded Zalicus (NASDAQ: ZLCS ) from Outperform to Perform and removed the $12.00 price target after disappointing Phase II studies of Z160. Z160 was being evaluated in a Phase IIa for lumbosacral radiculopathy (LSR) and a second phase for postherpetic
